NuVasive Announces Upcoming Departure of Chief Financi...(The potential risks and uncertainties th...),Health

Date:9/2/2009

The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    CONTACT:
    Kevin C. O'Boyle
    EVP & Chief Financial Officer
    NuVasive, Inc.
    +1-858-909-1998
    investorrelations@nuvasive.com

    Investors:
    Patrick F. Williams
    Vice President, Finance
    NuVasive, Inc.
    +1-858-638-5511
    investorrelations@nuvasive.com

    Media:
    Jason Rando
    The Ruth Group
    +1-646-536-7025
    jrando@theruthgroup.com

'/>"/>

SOURCE NuVasive, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
9. NuVasive Reports First Quarter 2008 Financial Results
10. NuVasive Acquires First Stem Cell Bone Graft Substitute
11. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference